Actavis seeks FDA authorization to market generic Opana ER Watson Pharmaceuticals.

Actavis seeks FDA authorization to market generic Opana ER Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Program with the U.S. Food and Drug Administration seeking authorization to advertise Oxymorphone Hydrochloride Extended-launch Tablets. Related StoriesKolltan announces demonstration of data from KTN0158 preclinical research in mast cell tumors at ESMO 2015Allergan settles patent litigation with Amneal linked to NAMENDA XR extended launch capsulesFDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult individuals with acromegaly On January 18 Endo and Grunenthal GmbH filed match against Actavis, 2013, in the U.S.The business intends to keep buying shares on view market from time to time.

ACE supports HHS’ National Strategy for Quality Improvement in Health Care The Accreditation for Cardiovascular Excellence , a nonprofit organization whose objective is to make sure high-quality patient care and promote patient safety in facilities where invasive cardiac and endovascular procedures are performed, works with the National Strategy for Quality Improvement in Health Care issued today by the U.S. Department of Health insurance and Human Providers .